2-amino-6-phenylhexanoic acid | 36061-05-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-6-phenylhexanoic acid
• 英文别名: 2-Amino-6-phenyl-hexansaeure；α-Amino-ε-phenyl-n-capronsaeure
• CAS: 36061-05-9
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: PZXDKILRPSNHBC-UHFFFAOYSA-N

物化性质

• 熔点：
  237-242 °C
• 沸点：
  386.0±42.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  rac-(2-phenylbutyl)propanedioic acid 在 乙醚 、 氨 、 溴 作用下， 生成 2-amino-6-phenylhexanoic acid
  参考文献：
  名称：

  v. Braun; Kruber, Chemische Berichte, 1912, vol. 45, p. 396

  摘要：

  DOI：

文献信息

• [EN] NEOSEPTINS: SMALL MOLECULE ADJUVANTS<br/>[FR] NÉOSEPTINES : PETITS ADJUVANTS MOLÉCULAIRES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014131023A1

  公开（公告）日：2014-08-28

  A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

  揭示了一种MD-2:TLR4复合物激动剂化合物，其结构对应于所定义的公式（I）。还公开了其制备和使用方法，以及含有该化合物的药物组合物。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• Comparative studies of the specificities of α-chymotrypsin and subtilisin BPN′. Studies with flexible and ‘locked’ substrates
  作者：T. N. Pattabiraman、W. B. Lawson

  DOI：10.1042/bj1260659

  日期：1972.2.1

  Subtilisin BPN′ hydrolysed N-acetyl-l-3-(2-naphthyl)-alanine methyl ester, N-acetyl-l-leucine methyl ester and N-acetyl-l-valine methyl ester, faster than α-chymotrypsin. Of eight ‘locked’ substrates tested, only methyl 5,6-benzindan-2-carboxylate was hydrolysed faster by subtilisin, whereas the other esters were better substrates for chymotrypsin. Compared with the values for chymotrypsin, the stereospecific ratios during the hydrolysis of the optically active locked substrates by subtilisin were decreased by one and two orders of magnitude for bi- and tri-cyclic substrates respectively. The polar groups adjacent to the α-carbon atom of locked substrates did not contribute significantly to the reactivity of the more active optical isomers, but had a detrimental effect on the less active antipodes during hydrolysis by both the enzymes. These studies show that the binding site of subtilisin BPN′ is longer and broader than that of α-chymotrypsin.

  Subtilisin BPN'水解N-乙酰基-L-3-(2-萘基)-丙氨酸甲酯、N-乙酰基-L-亮氨酸甲酯和N-乙酰基-L-缬氨酸甲酯的速度比α-胰蛋白酶快。在测试的八个“锁定”底物中，只有甲基5,6-苯并二氢萘-2-羧酸酯被Subtilisin更快地水解，而其他酯类底物则更适合胰蛋白酶。与胰蛋白酶相比，通过Subtilisin水解光学活性锁定底物时，立体比值分别降低了一个和两个数量级，对于双环和三环底物而言。锁定底物α-碳原子邻近的极性基团对更活跃的光学异构体的反应没有显著贡献，但在两种酶水解过程中对较不活跃的对映体有不利影响。这些研究表明，Subtilisin BPN'的结合位点比α-胰蛋白酶的结合位点更长更宽。
• Oral GLP-1 formulations
  申请人：Sarubbi J. Donald

  公开号：US20060286129A1

  公开（公告）日：2006-12-21

  The present invention provides phamaceutical compositions comprising at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.

  本发明提供了包含至少一种给药剂和GLP-1的制药组合物。这些制药组合物促进GLP-1的口服给药，相比不含给药剂的GLP-1给药，提供了改善的（如增加的）GLP-1生物利用度。
• Compounds and compositions for delivering active agents
  申请人：Emisphere Technologies, Inc.

  公开号：US20030008900A1

  公开（公告）日：2003-01-09

  Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

  本发明提供了用于传递活性物质的载体化合物和组合物。同时还提供了其管理和制备方法。